Entrada Therapeutics (TRDA) Stock Forecast, Price Target & Predictions
TRDA Stock Forecast
Entrada Therapeutics stock forecast is as follows: an average price target of $18.00 (represents a 1.29% upside from TRDA’s last price of $17.77) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
TRDA Price Target
TRDA Analyst Ratings
Entrada Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jun 25, 2024 | Raghuram Selvaraju | H.C. Wainwright | $18.00 | $14.24 | 26.40% | 1.29% |
Entrada Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 1 |
Avg Price Target | - | - | $18.00 |
Last Closing Price | $17.77 | $17.77 | $17.77 |
Upside/Downside | -100.00% | -100.00% | 1.29% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Aug 14, 2024 | Cowen & Co. | Buy | Buy | Hold |
Jun 25, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Jun 24, 2024 | Cowen & Co. | Buy | Buy | Hold |
Nov 22, 2023 | William Blair | Outperform | Outperform | Hold |
Entrada Therapeutics Financial Forecast
Entrada Therapeutics Revenue Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $41.85M | $43.73M | - | $25.26M |
Avg Forecast | $14.11M | $14.11M | $14.11M | $14.11M | $11.64M | $11.64M | $11.64M | $11.64M | $9.76M | $12.32M | $51.86M | $14.98M | $23.69M | $9.60M | $9.78M | $7.00M |
High Forecast | $14.11M | $14.11M | $14.11M | $14.11M | $11.64M | $11.64M | $11.64M | $11.64M | $9.76M | $15.16M | $51.86M | $14.98M | $31.08M | $9.60M | $9.78M | $7.00M |
Low Forecast | $14.11M | $14.11M | $14.11M | $14.11M | $11.64M | $11.64M | $11.64M | $11.64M | $9.76M | $9.48M | $51.86M | $14.98M | $12.01M | $9.60M | $9.78M | $7.00M |
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.77% | 4.56% | - | 3.61% |
Entrada Therapeutics EBITDA Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $5.64M | $14.01M | - | $-5.78M |
Avg Forecast | $11.28M | $11.28M | $11.28M | $11.28M | $9.30M | $9.30M | $9.30M | $9.30M | $7.80M | $9.85M | $41.46M | $11.97M | $18.94M | $7.67M | $7.82M | $5.60M |
High Forecast | $11.28M | $11.28M | $11.28M | $11.28M | $9.30M | $9.30M | $9.30M | $9.30M | $7.80M | $12.12M | $41.46M | $11.97M | $24.85M | $7.67M | $7.82M | $5.60M |
Low Forecast | $11.28M | $11.28M | $11.28M | $11.28M | $9.30M | $9.30M | $9.30M | $9.30M | $7.80M | $7.58M | $41.46M | $11.97M | $9.61M | $7.67M | $7.82M | $5.60M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.30% | 1.83% | - | -1.03% |
Entrada Therapeutics Net Income Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-9.54M | $35.46M | - | $-6.67M |
Avg Forecast | $-36.95M | $-34.89M | $-32.99M | $-31.96M | $-33.61M | $-34.68M | $-32.90M | $-32.07M | $-27.98M | $-25.85M | $12.83M | $-21.09M | $-5.98M | $-26.10M | $-24.49M | $-23.12M |
High Forecast | $-36.95M | $-34.89M | $-32.99M | $-31.96M | $-33.61M | $-34.68M | $-32.90M | $-32.07M | $-27.98M | $-18.13M | $12.84M | $-21.09M | $17.94M | $-26.10M | $-24.49M | $-23.12M |
Low Forecast | $-36.95M | $-34.89M | $-32.99M | $-31.96M | $-33.61M | $-34.68M | $-32.90M | $-32.07M | $-27.98M | $-33.95M | $12.82M | $-21.09M | $-45.28M | $-26.10M | $-24.49M | $-23.12M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.60% | -1.36% | - | 0.29% |
Entrada Therapeutics SG&A Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $8.65M | $7.53M | - | $7.94M |
Avg Forecast | $11.99M | $11.99M | $11.99M | $11.99M | $9.89M | $9.89M | $9.89M | $9.89M | $8.30M | $10.47M | $44.08M | $12.73M | $20.14M | $8.16M | $8.31M | $5.95M |
High Forecast | $11.99M | $11.99M | $11.99M | $11.99M | $9.89M | $9.89M | $9.89M | $9.89M | $8.30M | $12.89M | $44.08M | $12.73M | $26.42M | $8.16M | $8.31M | $5.95M |
Low Forecast | $11.99M | $11.99M | $11.99M | $11.99M | $9.89M | $9.89M | $9.89M | $9.89M | $8.30M | $8.06M | $44.08M | $12.73M | $10.21M | $8.16M | $8.31M | $5.95M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.43% | 0.92% | - | 1.33% |
Entrada Therapeutics EPS Forecast
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.29 | $1.07 | - | $-0.21 |
Avg Forecast | $-1.04 | $-0.98 | $-0.93 | $-0.90 | $-0.95 | $-0.98 | $-0.93 | $-0.90 | $-0.79 | $-0.73 | $0.36 | $-0.59 | $-0.17 | $-0.73 | $-0.69 | $-0.65 |
High Forecast | $-1.04 | $-0.98 | $-0.93 | $-0.90 | $-0.95 | $-0.98 | $-0.93 | $-0.90 | $-0.79 | $-0.51 | $0.36 | $-0.59 | $0.51 | $-0.73 | $-0.69 | $-0.65 |
Low Forecast | $-1.04 | $-0.98 | $-0.93 | $-0.90 | $-0.95 | $-0.98 | $-0.93 | $-0.90 | $-0.79 | $-0.96 | $0.36 | $-0.59 | $-1.28 | $-0.73 | $-0.69 | $-0.65 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.72% | -1.46% | - | 0.32% |
Entrada Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
PMVP | PMV Pharmaceuticals | $1.64 | $24.75 | 1409.15% | Buy |
MOLN | Molecular Partners | $6.06 | $29.00 | 378.55% | Buy |
PEPG | PepGen | $6.79 | $29.50 | 334.46% | Buy |
OPT | Opthea | $4.21 | $14.00 | 232.54% | Buy |
VIGL | Vigil Neuroscience | $3.87 | $11.00 | 184.24% | Buy |
LRMR | Larimar Therapeutics | $7.57 | $20.33 | 168.56% | Buy |
ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
TYRA | Tyra Biosciences | $16.42 | $30.50 | 85.75% | Buy |
PHVS | Pharvaris | $23.93 | $39.67 | 65.78% | Buy |
CNTA | Centessa Pharmaceuticals | $15.89 | $21.67 | 36.38% | Buy |
THRD | Third Harmonic Bio | $12.11 | $16.15 | 33.36% | Buy |
EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
CRNX | Crinetics Pharmaceuticals | $56.82 | $70.14 | 23.44% | Buy |
IRON | Disc Medicine | $58.25 | $66.86 | 14.78% | Buy |
TRDA | Entrada Therapeutics | $17.77 | $18.00 | 1.29% | Buy |
TRDA Forecast FAQ
Is Entrada Therapeutics a good buy?
Yes, according to 3 Wall Street analysts, Entrada Therapeutics (TRDA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of TRDA's total ratings.
What is TRDA's price target?
Entrada Therapeutics (TRDA) average price target is $18 with a range of $18 to $18, implying a 1.29% from its last price of $17.77. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Entrada Therapeutics stock go up soon?
According to Wall Street analysts' prediction for TRDA stock, the company can go up by 1.29% (from the last price of $17.77 to the average price target of $18), up by 1.29% based on the highest stock price target, and up by 1.29% based on the lowest stock price target.
Can Entrada Therapeutics stock reach $30?
TRDA's average twelve months analyst stock price target of $18 does not support the claim that Entrada Therapeutics can reach $30 in the near future.
What are Entrada Therapeutics's analysts' financial forecasts?
Entrada Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $46.54M (high $46.54M, low $46.54M), average EBITDA is $37.21M (high $37.21M, low $37.21M), average net income is $-133M (high $-133M, low $-133M), average SG&A $39.56M (high $39.56M, low $39.56M), and average EPS is $-3.753 (high $-3.753, low $-3.753). TRDA's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $56.42M (high $56.42M, low $56.42M), average EBITDA is $45.11M (high $45.11M, low $45.11M), average net income is $-137M (high $-137M, low $-137M), average SG&A $47.96M (high $47.96M, low $47.96M), and average EPS is $-3.853 (high $-3.853, low $-3.853).
Did the TRDA's actual financial results beat the analysts' financial forecasts?
Based on Entrada Therapeutics's last annual report (Dec 2023), the company's revenue was $129.01M, beating the average analysts forecast of $50.06M by 157.71%. Apple's EBITDA was $-3.162M, missing the average prediction of $40.02M by -107.90%. The company's net income was $-6.685M, missing the average estimation of $-79.692M by -91.61%. Apple's SG&A was $32.29M, missing the average forecast of $42.56M by -24.12%. Lastly, the company's EPS was $-0.0002, missing the average prediction of $-2.244 by -99.99%. In terms of the last quarterly report (Dec 2023), Entrada Therapeutics's revenue was $41.85M, beating the average analysts' forecast of $23.69M by 76.66%. The company's EBITDA was $5.64M, missing the average prediction of $18.94M by -70.21%. Entrada Therapeutics's net income was $-9.544M, beating the average estimation of $-5.98M by 59.60%. The company's SG&A was $8.65M, missing the average forecast of $20.14M by -57.03%. Lastly, the company's EPS was $-0.29, beating the average prediction of $-0.168 by 72.19%